Darbepoetin alfa, an erythropoiesis-stimulating agent (ESA) used to treat renal anemia, might have anti-proteinuric effects in patients with diabetic kidney disease.

The novel erythropoetic protein darbepoetin alfa exhibits enhanced biological activity and increased serum half-life compared with other erythropoetic agents used to treat chemotherapy-related anemia.

Please provide your email address to receive an email when new articles are posted on . Vadadustat demonstrated the efficacy and cardiovascular safety for the treatment of anemia in adult patients ...

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...

According to the results of a single-center, prospective, crossover study, darbepoetin alfa—a hyperglycosylated, and therefore longer-acting, derivative of epoetin—is a more effective treatment for ...

Pilot study to determine the effects of dronabinol on hot flash relief in breast cancer patients Background: Anemia occurring in cancer patients undergoing Chemotherapy and or Radiotherapy causes ...

Cipla collaborates with Hetero to launch its second biosimilar drug 'Darbepoetin alfa' ~Patients with chronic kidney disease and anaemia set to gain~ India, Mumbai, 19th June 2014: Cipla, a global ...

Feasibility of withholding dexamethasone premedication in patients not experiencing two previous cycles of weekly paclitaxel related infusion hypersensitivity reaction. This is an ASCO Meeting ...

The FDA previously updated the boxed warning for all erythropoiesis-stimulating agents (darbepoetin [Aranesp], epoetin alfa (Epogen, Procrit]) because of increased risk of serious and life-threatening ...

A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new research and collaboration between researchers at Intermountain Health in Salt ...

In a correction study involving 1751 patients, vadadustat proved noninferior to darbepoetin with a least square mean difference in hemoglobin (Hb) of 0.05g/dL (the prespecified noninferiority ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio In an evaluation of four phase 3 trials ...